Effect of Olanzapine and Aripiprazole in schizophrenic patients

Comparison of therapeutic effects of Citalopram and Olanzapine with Citalopram and Aripiprazole in Schizophrenia patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013090714577N1

Enrollment

Registered

2014-12-06

Start date

2013-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Citalopram(Sobhandarou) dose of 40mg/day plus Olanzapine (Sobhandarou) dose of 15mg per day for 8 weeks. Intervention 2: Control group: Citalopram(Sobhandarou) dose

Treatment - Drugs

Intervention group: Citalopram(Sobhandarou) dose of 40mg/day plus Olanzapine (Sobhandarou) dose of 15mg per day for 8 weeks.

Control group: Citalopram(Sobhandarou) dose of 40mg/day plus Aripiprazole (Bakhtar-Bioshimi-Company) dose of 20mg per day for 8 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 52 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosis of schizophrenia according to the criteria of DSM-IV-TR ; Referred to the psychiatric clinic Fatemi Hospital. Exclusion criteria:Individual or patient reluctance to participate in the study; History of other psychiatric disorders, patients who are currently treated with other drugs; History of known medical condition under treatment .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Brief Psychiatric Rating Scale. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: individual's self-report.;Blood Pressure. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: mm/hg.;Weight. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Kg.;Positive and Negative Syndrome Scale. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Clinical Interview.;Insomnia. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Anxiety. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Drowsiness. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Weakness. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Headache. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Self-reported.;Restlessness. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Xerostomia. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Aggression. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation.;Nausea. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Vomiting. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Tremor. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Extrapyramidal side effects. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observ	—

Measure

Time frame

Brief Psychiatric Rating Scale. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: individual's self-report.;Blood Pressure. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: mm/hg.;Weight. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Kg.;Positive and Negative Syndrome Scale. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Clinical Interview.;Insomnia. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Anxiety. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Drowsiness. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Weakness. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Headache. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Self-reported.;Restlessness. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Xerostomia. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Aggression. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation.;Nausea. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Vomiting. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Tremor. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observation and Self-reported.;Extrapyramidal side effects. Timepoint: Pre-intervention and eight weeks after intervention. Method of measurement: Observ

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Ghyami

Ardabil University of Medical Sciences

yalgiz.q@gmail.com+98 41 1385 0951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026